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Summary
Purpose: In patients with epilepsy, although many changes in the physiology of
hormones in the neuroendocrine system can occur (especially in the sex hormones,
for example), the causes of these changes have not been fully elucidated. There are
also relations between seizure activity and stages of sleep. Ghrelin is the peptide
hormone, which has been shown to affect both endocrine function and sleep. The
purpose of this study was to evaluate serum levels of ghrelin in epilepsy patients.
Methods: A total of 35 patients currently receiving antiepileptic drug therapy (of
these patients, 20 had primary generalized seizure and 15 had partial seizure) were
studied. The control group consisted of 30 healthy volunteers matched for age and
gender. In all participants, serum levels of ghrelin, cholesterol and triglycerides were
measured and body mass index (BMI) was determined. Patients with endocrine,
immune or any other chronic diseases were excluded.
Results: In the epilepsy patients, the mean serum ghrelin level was 158.81
 55.97 pg/ml, and this was significantly higher than the control group’s level of
93.43  21.33 pg/ml ( p < 0.001). In terms of serum cholesterol, triglycerides and
BMI, no significant differences were found between the epilepsy patients and the
control group ( p > 0.05).
Conclusions: The origin of higher serum ghrelin levels in epilepsy and their relation to
seizures are not completely known. However, this elevation of serum ghrelin could
contribute to the lengthening of NREM sleep in epilepsy patients, thereby playing a
role in seizure occurrence. From another direction, high serum ghrelin levels could
cause changes and/or dysfunction in hormone secretion and physiology via its effects
on growth hormone, and thereby play a facilitating role in seizure occurrence.
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Relations betweenepilepsyand theendocrine system
have attracted the attention of researchers for many
years.1,2 It is known that the severity of epileptic
seizures is related to temporary changes in secretions
of circadian-modulated hormones.3 For example,
after severeprimary or secondary generalizedpartial
seizures, serum levels of prolactin, noradrenalin,
vasopressin and oxytocin increase.4 Changes in the
balance of sex hormones have also been noted in
patients with epilepsy.5,6 In particular, when activity
in the temporolimbic region is disrupted by recurrent
or persistent interictal epileptiform discharges, a
path can be opened for changes in the hypothalamo-
pituitary regulation of gonadal secretion, possibly
leading to dysfunction in the reproductive endocrine
system.7,8 A link between seizures and impairment of
thehypothalamicpituitaryadrenocortical systemhas
also been shown.9
In patients with epilepsy, sleep disorders are
common, but they are diverse and complex.10,11 A
connection between sleep and epilepsy has long
been established,12,13 and it has been shown that
physiologic changes involved in the non-rapid-eye-
movement (NREM) sleep are associated with
increased susceptibility to seizures.10,13 From this
it is known that stages of sleep have an important
role in seizure occurrence.10,12
Recently, the polypeptide hormone ghrelin has
been recognized as an endogenous ligand to the
growth hormone secretagogue receptor (GHSR),
and has been isolated from stomach, hypothalamus
and other tissues.14,15 Although ghrelin is secreted
mainly by stomach mucosa, it is widely expressed in
other tissues, and in this way it may have both
endocrine and paracrine effects.15 Ghrelin has been
reported to affect cardiac and gastrointestinal func-
tion, carbohydrate metabolism, adipose and repro-
ductive tissue, cell proliferation and behavior as
well as affecting sleep and pituitary hormone axis
function.14—16
Given the multiple links between epilepsy, sleep
and endocrine function on the one hand and
between ghrelin, sleep and endocrine function on
the other, the purpose of this study was to look for
changes in serum ghrelin levels in patients with
epilepsy. To our knowledge, this is the first clinical
study to investigate this question.
Methods
The protocol of this study was approved by our
institution’s Ethics Committee. Each patient was
informed about the study and signed a consent formbefore participating. A total of 35 patients currently
being followed by and receiving treatment from the
Department of Neurology at Firat University Medical
Center were included in the study. Of these
patients, 20 had primary generalized seizure and
15 had partial seizure, according to the Interna-
tional League Against Epilepsy (ILAE) classifica-
tion.17 In the primary generalized epilepsy group,
there were 12 females and 8 males, with an overall
mean age of 34.25  10.37 years. The duration
between diagnosing and initiation of therapy was
2.06  0.27 years. Twenty patients in the primary
generalized group had generalized tonic-clonic sei-
zure; 16 were treated with valproic acid and 4 with
phenytoin for seizure control. While before therapy
the patients with generalized tonic-clonic seizures
had an average of 9.08  2.06 seizures per year,
seizures had not occurred for approximately 5
months.
In the partial epilepsy group, there were eight
females and seven males, with an overall mean age
of 27.43  7.1 years. The mean time since diagnosis
and initiation of therapy was 2.5  0.40 years. While
this group of patients had been experiencing an
average of 10.64  3.78 seizures per year before
therapy, no seizures were observed in the last 4
months. In this group, 5 patients had simple partial
seizure and were taking carbamazepine for seizure
control, while the other 10 patients had complex
partial seizure and were taking valproic acid (see
Table 1).
Exclusion criteria were as follows: presence of
any concurrent psychiatric disease; except for anti-
epileptic drugs, regular drug use including oral con-
traceptives; other diseases (neurological, endocrin-
ological, rheumatological, hematological, acute or
chronic infectious and/or inflammatory), liver or
kidney dysfunction, substance or alcohol abuse, or
a body mass index (BMI) over 25. The control group
consisted of 30 healthy volunteers matched for age
and gender.
Each patient had a complete physical and neu-
rological examination prior to being enrolled in the
study. Electroencephalography (EEG) as well as
computerized tomography (CT) or magnetic reso-
nance imaging (MRI) of the brain was performed in
all patients. Baseline laboratory investigations
included white blood cell count, red blood cell
count, creatinine, electrolytes, GOT, GPT, AP,
gGT, partial thromboplastin time, sedimentation
rate, C-reactive protein, serum iron, transferrin
and glucose. Thyroid function tests were per-
formed, and serum levels of cholesterol and trigly-
cerides were measured. Serum lipid levels were
specifically measured in this study due to their
effect on the serum ghrelin levels. Pelvic ultrasono-
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Table 1 Characteristics of epilepsy patients and healthy controls
Primary generalized
epilepsy (GTC) (n = 20)
Partial epilepsy (n = 15) Controls (n = 30)
Simple PE (n = 5) Complex PE (n = 10)
Age (years) 34.25  10.37 29.5  8.93 24.22  5.21 28.34  9.72
Gender
Female 12 3 6 14
Male 8 2 4 16
Therapy
CBZ — 5 — —
VPA 16 — 10 —
PHT 4 — — —
JME: juvenile myoclonic epilepsy; GTC: generalized tonic-clonic epilepsy; PE: partial epilepsy; CBZ: carbamazepine; VPA: valproic
acid; PHT: phenytoin.graphy was performed to exclude polycystic ovary
disease in the female participants. Height and
weight were measured in all patients and healthy
control subjects.
Serum ghrelin levels were measured in fasting
blood samples taken from participants’ antecubital
veins at 8 a.m. The blood samples were immediately
centrifuged, and until the time of the ghrelin assay,
sera were kept at 80 8C. Serum ghrelin concentra-
tions were measured with a commercial radioimmu-
noassay (RIA) kit (Phoenix Pharmaceuticals Inc.,
Phoenix, AZ, USA) that employs I-125 labeled bioac-
tive ghrelin as a tracer and a rabbit polyclonal
antibody against full-length octanoylated human
ghrelin. The assay detects both ghrelin and des-
octanoyl-ghrelin. The sensitivity of the assay is
30 pg/ml, and the intra- and interassay coefficients
of variation are <5% and <14%, respectively.
Data were evaluated statistically with SPSS 10.1
software. Between-group comparisons were made
via one-way ANOVA, and the Tukey B and Scheffe´
tests were used as post hoc tests. Values obtained in
this study are given as mean  standard deviation.
In statistical evaluations, p < 0.05 was accepted as
significant.Table 2 Ghrelin, cholesterol, triglycerides and BMI values
Group of all
epilepsy patients
(n = 35)
Primary generalize
epilepsy group
(n = 20)
Ghrelin (pg/ml) 158.81  55.97a 134.45  39.29a
T cholesterol
(mg/dL)
192.57  42.69 195.90  45.58
Triglycerides
(mg/dL)
164.51  42.89 161.32  32.85
BMI 22.82  3.75 24.25  3.86
Values are given as mean  standard deviation.
a Comparison of patient group with control group via one-way AN
b Partial epilepsy group compared to primary generalized group vResults
In the group of 35 epilepsy patients, serum ghrelin
levels were significantly higher than in the healthy
control group ( p < 0.001, one-way ANOVA). When
the group of 20 patients with primary generalized
epilepsy and the group of 15 patients with partial
epilepsy were each compared to the control group
separately, their serum ghrelin levels were signifi-
cantly higher ( p < 0.001 in both groups, one-way
ANOVA). When two groups of epilepsy patients were
compared to each other, serum ghrelin levels in the
partial epilepsy group were found to be significantly
higher ( p < 0.001, one-way ANOVA).
In terms of serum cholesterol, triglyceride levels
and BMI values, no significant differences were
found between the overall group of 35 epilepsy
patients and the control group (p > 0.05, one-
way ANOVA). When the primary generalized epilepsy
group and the partial epilepsy group were compared
separately to the control group in terms of serum
cholesterol, triglyceride levels and BMI values, no
significant differences were found ( p > 0.05, one-
way ANOVA). These findings in the epilepsy patients
and healthy controls are summarized in Table 2.in the epilepsy patient groups and control group
d Partial
epilepsy group
(n = 15)
Control group
(n = 30)
p-values
234.06  36.47a, b 93.43  21.33 <0.001
185.46  38.89 187.98  47.67 >0.05
169.06  42.89 165.54  58.93 >0.05
23.92  2.68 22.75  4.31 >0.05
OVA, p < 0.001.
ia one-way ANOVA, p < 0.001.
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To our knowledge, this is the first study to examine
serum ghrelin levels in epilepsy patients. In the
overall group of 35 epilepsy patients included in
the study, serum ghrelin levels were found to be
significantly higher than in the control group
( p < 0.001, one-way ANOVA). Serum ghrelin levels
in the 20 patients with primary generalized epilepsy
and in the 15 patients with partial epilepsy were
likewise found to be higher when these two patient
groups were compared separately to the control
group (p < 0.001, one-way ANOVA).
Due to complaints of hormonal imbalances seen
in epilepsy patients, many studies have examined
the relations between the endocrine system and
epilepsy. It has been shown that epileptic seizures
can change serum levels of some hormones, espe-
cially hypothalamic trophic hormones and pituitary
hormones.18,19 These changes can be observed
immediately after epileptic seizures as acute and
short-term changes in hormone levels. After gen-
eralized tonic-clonic or prolonged, severe second-
ary generalized partial seizures, serum levels of
prolactin, vasopressin and oxytocin have been
shown to rise.3,4 Seizures can also lead to dysfunc-
tion in the hypothalamic—pituitary—gonadal axis,
which is modulated by temporal and limbic cortex.18
Regions in the limbic cortex such as the amygdala
have especially dense reciprocal connections with
the hypothalamus.18 In the amygdala, the cortico-
medial nuclei stimulate the pulse frequency of
gonadotropin releasing hormone (GnRH) secretion
by the hypothalamus, while the basolateral nuclei
inhibit the pulse frequency of GnRH.18 Especially in
female patients with temporolimbic epilepsy, it has
been reported that reproductive endocrine dysfunc-
tion and disorders are not rare.7 It has been sug-
gested that temporal originated recurrent or
persistent epileptiform discharges during interictal
period, may promote the development of reproduc-
tive endocrine disorders by causing chronically
changes in hypothalamopituitary regulation.7 As a
result, chronic changes in gonadal hormone secre-
tion and menstrual cycle disorders may occur. It is in
this way that reproductive endocrine disorders and
reproductive dysfunction are seen in these female
patients.7,8 This situation is independent of the
acute and short-term hormonal changes induced
by seizures in epileptic patients, and is significant
in terms of its being an example of epilepsy-induced
chronic endocrine dysfunction.
Another link between epilepsy and endocrine
function is that in patients receiving growth hor-
mone (GH) replacement therapy, a reported side
effect is epileptic seizures.21 In a 10-year study thatevaluated adverse events in GH replacement ther-
apy, seizures were ranked seventh among side
effects and were seen in 0.49% of patients.22
Ghrelin is a peptide hormone, and is an endogen-
ous ligand of the growth hormone secretagogue
receptor.14—16 In humans, ghrelin has been isolated
in stomach, hypothalamus and other tissues.14—16,20
In addition to its effects on regulation of appetite
and food intake, ghrelin has also been shown to play
a role in regulating the release of GH, adrenocorti-
cotropic hormone (ACTH) and prolactin.15 In this
regard, it may be proposed that high levels of
ghrelin, by affecting GH and prolactin secretion
and thereby disrupting hormonal equilibrium, may
facilitate the occurrence of seizures. However, we
do not know why serum ghrelin levels were elevated
in the group of epilepsy patients in this study.
Ghrelin has been shown to be a factor in sleep
regulation in humans.14 In a study in which healthy
young males were given ghrelin, the time spent in
slow-wave sleep increased overall during the night
and non-rapid-eye-movement (REM) sleep was
increased during the night.14 Stages of sleep are
also related to patterns of seizure occur-
rence.10,12,13 Epileptiform EEG discharges probably
multiply during NREM sleep, given that seizures
generally emerge in the NREM sleep. NREM is char-
acterized by a background of synchronized cellular
discharge patterns and decreased tone, which are
also a sign of decreased wakefulness. In contrast,
REM sleep resists the emergence of epileptiform
EEG potentials.12 In this study, in both the patient
and control groups, overnight fasting serum ghrelin
levels were measured at 8 a.m. It is known that
ghrelin secretion in healthy, non-obese individuals
shows a diurnal course and that ghrelin levels
increase at night.23 Furthermore, in patients with
Prader-Willi syndrome which typically have ele-
vated ghrelin levels, serial measurements in both
the patient and control groups showed that ghrelin
level elevation was consistent with a diurnal pattern
and that in every measurement ghrelin levels were
higher than in the control group.24 Thus, although a
single measurement is made, always at 8 a.m., our
results clearly indicate that serum levels of ghrelin
in the group of epilepsy patients were significantly
higher than the control group.
Thus, given ghrelin’s capacity to prolong NREM
sleep–—the stage in which seizures tend to occur–—
the high serum levels of ghrelin in our epilepsy
patients might be interpreted as a contributing
factor in the occurrence of seizures.
In the patients with partial epilepsy, serum ghre-
lin levels were significantly higher than in the
patients with primary generalized epilepsy
(p < 0.001, one-way ANOVA). The difference in
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interesting finding, and might be due to the epilep-
tic discharges having different origins and routes of
spread. The difference in ghrelin levels found
between the two groups of epilepsy patients might
be explained in terms of epileptiform discharges. It
is known that in adults, most localized seizures
originate in temporolimbic structures that include
hippocampus and amygdala.25,26 Dysfunction in the
temporolimbic region due to epileptiform activity
has been shown to disrupt hypothalamopituitary
regulation.6—8,18 This suggests a possibility that
the higher serum ghrelin levels we observed in
patients with partial epilepsy are mediated by the
effects of epileptiform discharges on the regulation
of ghrelin by the hypothalamus.
The use of antiepileptic drugs by the patients in
this study raises the question of whether those drugs
might affect serum ghrelin levels. We have not
encountered any information regarding this ques-
tion. Neuroleptic agents, which affect the central
nervous system, have been reported to increase
serum ghrelin levels.27 However, the mechanisms
of action of anticonvulsant agents are different from
those of neuroleptic drugs.
However, the capacity of epilepsy to impair reg-
ulation in the hypothalamopituitary axis indepen-
dent of medication has been reported.9 Among the
patients with epilepsy, 10 in the partial epilepsy
group and 16 in the generalized epilepsy group were
using the anticonvulsant agent valproic acid.
A majority of patients in each group were receiv-
ing valproic acid therapy, and the finding that
significantly different levels of elevated serum
ghrelin between the groups is a phenomenon pos-
sible independent from drug effects. It is therefore
possible that the high serum levels of ghrelin
observed in our epilepsy patients were indepen-
dent of drug effects.
However, it is not known whether serum ghrelin
levels differ in epilepsy patients in terms of whether
seizures are controlled by drug therapy. In the
epilepsy patients, serum ghrelin levels were mea-
sured in the interictal period. Also, the patients’
seizures were under control with anticonvulsant
drugs, and none of the patients had experienced
a seizure for approximately the last 4 months.
Whether epileptic seizures affect serum ghrelin
levels acutely is also unknown. We feel that further
studies can shed light on these questions.
In summary, given ghrelin’s capacity to affect
neuroendocrine physiology and the stages of sleep,
both of which are linked to epilepsy, it may be
suggested that high serum levels of ghrelin found
in epilepsy patients indicate a predisposition toward
seizure activity.References
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